Sean Ianchulev


Sean Ianchulev joined Tullis Health Investors in 2008 as a member of the Advisory Board, bringing extensive pharmaceutical development and clinical expertise to the firm.

Sean is Chief Medical Officer of Transcend Medical, Inc., a device company focused on glaucoma and the first spinout of ForSight Labs, a Menlo Park-based incubator focused solely on ophthalmic innovations.

Previously, Sean was was the group medical director for the ophthalmology division and the Lucentis franchise at Genentech. In this role, he headed clinical development and medical affairs activities and was instrumental to the launch and success of Lucentis, a multi-billion dollar bio-therapeutic for the treatment of age-related macular degeneration. Sean also has deep experience with medical devices. As the founder of the Peristat Group, Inc., he developed the first diagnostic device for remote telemonitoring of visual function and disease management of patients with glaucoma and macular degeneration.

Sean received his medical degree and a master's of public health from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. As a practicing ophthalmic surgeon and glaucoma specialist, he is well published in the field of ophthalmology and currently serves as an Assistant Clinical Professor of Ophthalmology at the University of California at San Francisco (UCSF).